We here propose a Specialized Program of Research Excellence in Breast Cancer to meet the needs of the oncologic community for an integrated clinical and laboratory effort dedicated to reducing the incidence of and mortality from breast cancer. The SPORE will be composed of one Director one Scientific Coordinator, a Steering Committee, five main research projects, two core resources (Administrative and Pathology), a Developmental Research Program, and a Career Development Program. The projects will include studies of erbB-2, erbB-3, and erbB-4, heregulin, EGFR, ras and farnesyl protein transferase inhibitors, TC- 21, TGF-beta, representational difference analysis, susceptibility genes (BRCA1), cyclins, and p53. These laboratory investigations will translate into a better understanding of etiology, diagnosis, staging, prognosis, therapeutic response, and quality-of-life. The Steering Committee will consist of the Director (Dr. Norton), the Scientific Coordinator (Dr. N. Rosen), the Head of the Breast Pathology Core Resource (Dr. P. P. Rosen), the leaders of the five main projects (Drs. Aaronson, Massague, Mendelsohn, N. Rosen, Wigler), Dr. Lucio Luzzatto (Human Genetics), Dr. Begg (Biostatistics), Dr. Lloyd Old (Immunology), Dr. Borgen (Surgery), Dr. Beryl McCormick (Radiation Therapy), and Ms. Amy Langer (Executive Director, National Alliance of Breast Cancer Organizations). To expedite an improved SPORE network, we advocate and will organize frequent meetings of the Directors of the funded SPOREs. We would also propose to coordinate our activities with those of representatives of the various NCI- sponsored tissue resource banks/registries other than the SPOREs, and with the chairs of the Cooperative Group Breast Cancer Committees. We have designed an extensive tissue resource to be of value to our SPORE and to the wider network that -we plan to organize. Oversight will be by MSKCC committees and by an eminent Board of Scientific Advisors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA068425-04
Application #
2703468
Study Section
Special Emphasis Panel (ZCA1-GRB-8 (M1))
Program Officer
Gomez, Jorge E
Project Start
1995-09-15
Project End
2000-08-31
Budget Start
1998-09-30
Budget End
1999-08-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Navin, Nicholas E; Hicks, James (2010) Tracing the tumor lineage. Mol Oncol 4:267-83
Ueda, Yukiko; Su, Yingjun; Richmond, Ann (2007) CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res 17:91-103
Solit, David B; Scher, Howard I; Rosen, Neal (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30:709-16
Mu, David; Chen, Liyun; Zhang, Xiping et al. (2003) Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell 3:297-302
Solit, David B; Basso, Andrea D; Olshen, Adam B et al. (2003) Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63:2139-44
Hamaguchi, Masaaki; Meth, Jennifer L; von Klitzing, Christine et al. (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A 99:13647-52
Munster, Pamela N; Marchion, Douglas C; Basso, Andrea D et al. (2002) Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Cancer Res 62:3132-7
Subbaramaiah, Kotha; Norton, Larry; Gerald, William et al. (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649-57
Basso, Andrea D; Solit, David B; Munster, Pamela N et al. (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21:1159-66
Solit, David B; Zheng, Fuzhong F; Drobnjak, Maria et al. (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-93

Showing the most recent 10 out of 51 publications